USPTO Examiner MITCHELL EDWIN COLEMAN - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18616089Methods of treating or reducing symptoms of brain cancer such as glioma and glioblastoma via combination therapy with allosteric modulators and phenethylamines.March 2024June 2025Abandon1521NoNo
18218312Simplified Method for Making Shelf Stable Highly Water Soluble Anhydrous Compositions Of Cyclodextrin Complexes of Macrocyclic LactonesJuly 2023August 2024Abandon1421YesNo
18126221LIQUID PHARMACEUTICAL FORMULATIONS OF TOPIRAMATEMarch 2023June 2024Allow1520YesNo
18114502LIQUID PHARMACEUTICAL COMPOSITIONS OF BACLOFEN FOR ORAL ADMINISTRATIONFebruary 2023July 2024Abandon1630YesNo
18154470PHARMACEUTICALLY STABLE PILOCARPINE FORMULATIONS WITH SUBSTANTIALLY REDUCED BUFFER CONTENT AND RELATED METHODSJanuary 2023November 2024Abandon2240NoNo
17985338Anhydrous Compositions Of Polysorbates For Shelf Stable Drug CombinationsNovember 2022March 2024Abandon1630YesNo
17922758An Antiperspirant CompositionNovember 2022June 2024Abandon1921NoNo
17721840MEDICATED DRINKApril 2022January 2025Abandon3341YesNo
17686928POLYMER BASED HYDROGELS, AEROGELS, AND COMBINATIONS THEREOFMarch 2022September 2024Abandon3120NoNo
17676224AQUEOUS LIQUID COSMETIC AND PEN-SHAPED COSMETIC PRODUCTFebruary 2022November 2024Abandon3321NoNo
17583636NANO- OR MICRO-EMULSION COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2022July 2024Abandon3021NoNo
17576804Fermented Composition for Topical Application to SkinJanuary 2022December 2023Abandon2311NoNo
17626914CONTINUOUS METHOD FOR NANO-EMULSIFICATION BY CONCENTRATION PHASE INVERSIONJanuary 2022November 2024Abandon3521NoNo
17290522MAMC-MEDIATED BIOMIMETIC NANOPARTICLESJanuary 2022June 2025Abandon4911NoNo
17564268LYOPHILIZED POWDER OF LATAMOXEF SODIUM FOR INJECTION AND LYOPHILIZATION METHOD THEREOFDecember 2021May 2025Allow4011YesNo
17645756Lip Gloss FormulationDecember 2021January 2024Abandon2501NoNo
17560328CREAMY HYDRATING COSMETIC COMPOSITION IN A WATER RELEASE EMULSIONDecember 2021January 2025Allow3731YesNo
17549970Method Of Manufacturing Cosmetic Compositions Comprising Sucrose Esters And SolventsDecember 2021June 2024Allow3040YesNo
17544228STABLE DISPERSIONS OF SILVER NANOPARTICLES AND METHODS OF PREPARATION THEREOFDecember 2021June 2025Allow4331YesNo
17534801TRANSDERMAL DRUG DELIVERY DEVICE/TRANSDERMAL PATCH AND OTHER APPLICATIONS OF EMULSION FORMULATIONNovember 2021June 2023Abandon1910NoNo
17612159METHODS AND COMPOSITIONS FOR TREATING UNDESIRED IMPLANTED TISSUE FILLERNovember 2021September 2024Allow3421YesNo
17525914INTRAVENOUS PHYSIOLOGICAL SOLUTION TO OPTIMIZE FLUID THERAPY IN PATIENTSNovember 2021March 2024Allow2821YesNo
17610660POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDSNovember 2021April 2025Abandon4131NoNo
17608347DI-THIOESTER CATIONIC LIPIDSNovember 2021June 2025Allow4311YesNo
17605585FUSOGENIC PARTICLES AND RELATED METHODS FOR DELIVERING THERAPEUTIC AGENTS TO CELLSOctober 2021January 2025Abandon3901NoNo
17481730COMPOSITION OF SUSPOEMULSION FORMULATION OF ANTHELMINTIC DRUGS WITH ESSENTIAL OILS FOR NASO-PULMONARY ADMINISTRATIONSeptember 2021September 2024Abandon3641YesNo
17476911PEPTIDE MICROPARTICLE STRUCTURESeptember 2021August 2023Abandon2301NoNo
17467955SKIN CARE FORMULA, SKIN CARE PRODUCTS, AND METHODS OF MAKING THE SAMESeptember 2021December 2024Allow3921YesNo
17443498TRANSMEMBRANE PORES FORMED BY AROMATIC OLIGOAMIDE FOLDAMERS AND USES OF SAMEJuly 2021October 2023Allow2711YesNo
17383817FUNCTIONALIZED SET OF CARBON ATOMS IN THE SP2 HYBRIDIZATION STATE, A METHOD FOR PREPARING IT AND ITS USES, IN PARTICULAR FOR RENDERING A SURFACE ANTIBACTERIALJuly 2021March 2025Abandon4431NoNo
17418337AGENT FOR INHIBITING REDUCTION IN DECOMPOSITION OF DENATURED ELASTIN, AGENT FOR MAINTAINING NORMAL ELASTIN FIBERS, AGENT FOR INHIBITING FORMATION OF ELASTIN-ELAFINE COMPOSITE, AND SCREENING METHOD FOR SUBSTANCE HAVING ELASTIN-ELAFINE COMPOSITE FORMATION INHIBITORY EFFECTJune 2021November 2024Abandon4101NoNo
17413091COMPOSITION COMPRISING A POLYSACCHARIDE, A POLYOL AND A SPECIFIC ESTERJune 2021February 2025Abandon4431NoNo
17315089POUCHESMay 2021September 2023Abandon2911NoNo
17291247COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND MICROTUBULE ASSEMBLY INHIBITOR HERBICIDESMay 2021September 2024Abandon4101NoNo
17246018Compositions and Methods for Treating Dopamine DisordersApril 2021December 2024Abandon4441NoNo
17238809SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONSApril 2021November 2024Allow4321YesYes
17287344Deep Eutectic Solvent Platform for Oral Pharmaceutical FormulationsApril 2021November 2024Abandon4221NoNo
17235314TRANSDERMAL AND/OR TOPICAL, PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAINApril 2021May 2025Abandon4831NoNo
17233493METHOD OF STABLE FORMULATION OF MICROBIAL AND MICROBE DERIVED PRODUCTS AND USE OF SAMEApril 2021June 2024Allow3831YesNo
17223671STABILIZED LIQUID ENZYME SUPPLEMENT AND USES THEREOFApril 2021May 2023Abandon2510NoNo
17282809CORE-SHELL STRUCTURE FOR ESTABLISHING NORMAL AND CANCER ORGANOID MICROENVIRONMENT AND FABRICATION METHOD THEREFORApril 2021November 2024Abandon4411NoNo
17220456ORAL DOSAGE FORM WITH SURFACE DELIVERY OF ACTIVE AGENTApril 2021March 2024Abandon3611NoNo
17219295METHODS AND COMPOSITIONS FOR DRUG DELIVERYMarch 2021May 2025Abandon4941NoNo
17214868SUPPOSITORIES COMPRISING CANNABINOIDSMarch 2021December 2023Abandon3320NoNo
17276478PHARMACEUTICAL COMPOSITIONS AND DELIVERY SYSTEMS FOR PREVENTION AND TREATMENT OF CANDIDIASISMarch 2021January 2024Abandon3411NoNo
17196567Novel Compounds and Pharmaceutical PreparationsMarch 2021July 2024Abandon4110NoNo
17274223FUNGICIDAL NITROANILINO SUBSTITUTED PYRAZOLESMarch 2021April 2025Allow5021YesNo
17250714CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONEFebruary 2021January 2025Abandon4721NoNo
17183157Immobilization of Plant Growth Promoting Microorganisms in Hydrophobic CarriersFebruary 2021May 2025Abandon5131NoYes
17268769METHOD FOR PREPARING MICROCAPSULEFebruary 2021March 2025Allow4921YesNo
17256522FERMENTED BIRCH SAP AND METHOD FOR PRODUCING ITDecember 2020August 2024Allow4421YesNo
17053429INJECTION FORMULATION COMPOSITION FOR USE AS FILLER OR DRUG CARRIER THROUGH CLICK CHEMISTRY REACTIONNovember 2020November 2024Abandon4941YesNo
17053434MICROBACTERIUM ISOLATES AND USES THEREOFNovember 2020April 2024Abandon4110NoNo
17047222HAIRCARE COMPOSITION COMPRISING MODIFIED VEGETABLE WAXESOctober 2020December 2024Allow5031YesNo
17046726METHOD OF CONTROLLING SOIL-BORNE DISEASES OF PLANTSOctober 2020April 2025Abandon5431NoNo
17045204WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE (HPPD) INHIBITORSOctober 2020February 2024Abandon4141NoNo
17045188WEED CONTROL FROM APPLICATIONS OF PYRIDINE CARBOXYLIC ACID HERBICIDES AND ACETYL CoA CARBOXYLASE (ACCase) INHIBITORSOctober 2020February 2024Abandon4041NoNo
17045178EMULSIFIABLE CONCENTRATE FORMULATIONS OF SDHI FUNGICIDESOctober 2020August 2024Abandon4730NoNo
16978215A COMPOSITION SUITABLE FOR HAIR CARESeptember 2020March 2024Abandon4321NoNo
16975747METHOD OF REDUCING CROP DAMAGEAugust 2020April 2023Abandon3210NoNo
16986745PLANT HEALTH WITH IN SITU FORMED WATER ABSORBING HYDROGELSAugust 2020March 2025Abandon5521NoNo
16945279CADAVER PRESERVATION SYSTEMS AND METHODSJuly 2020March 2023Allow3210YesNo
16966704FIVE-MEMBERED RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOFJuly 2020April 2024Allow4511YesNo
16966686PYRIDINE RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOFJuly 2020April 2024Allow4511YesNo
16966452GLASS FORMULATIONS AND USES THEREOFJuly 2020June 2023Abandon3511NoNo
16916594COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL CONTAINING A COMBINATION OF SILICONE RESINSJune 2020February 2025Allow5551YesNo
16500688PROCESS FOR DYEING HAIR COMPRISING AT LEAST ONE PIGMENT, AT LEAST ONE ACRYLATE-FUNCTIONALIZED POLYMER AND AT LEAST ONE FUNCTIONALIZED SILICONE CHOSEN FROM SILICONES FUNCTIONALIZED WITH AT LEAST ONE MERCAPTO OR THIOL GROUPOctober 2019May 2024Allow5551YesNo
16468423PUFA SALT FORMULATIONS (II)June 2019March 2024Abandon5751NoNo
16091219PERSONAL CARE COMPOSITIONS AND METHODS FOR USING SUCH COMPOSITIONSOctober 2018September 2024Allow6061YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MITCHELL, EDWIN COLEMAN.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
3
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MITCHELL, EDWIN COLEMAN - Prosecution Strategy Guide

Executive Summary

Examiner MITCHELL, EDWIN COLEMAN works in Art Unit 1619 and has examined 68 patent applications in our dataset. With an allowance rate of 32.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner MITCHELL, EDWIN COLEMAN's allowance rate of 32.4% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MITCHELL, EDWIN COLEMAN receive 2.24 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MITCHELL, EDWIN COLEMAN is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +78.6% benefit to allowance rate for applications examined by MITCHELL, EDWIN COLEMAN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.9% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 13.0% of cases where such amendments are filed. This entry rate is in the 7% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.4% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.